•
DN
DNLI
Denali Therapeutics Inc. Common Stock
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
2.90B
Volume
1.78M
52W High
$24.35
52W Low
$10.57
Open
$0.00
Prev Close
$17.53
Day Range
0.00 - 0.00
About Denali Therapeutics Inc. Common Stock
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Latest News
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
GlobeNewswire Inc.•Dec 30
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.•Dec 10
Denali Therapeutics Announces Board and Executive Leadership Updates
GlobeNewswire Inc.•Nov 6
Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034
GlobeNewswire Inc.•Oct 17
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
GlobeNewswire Inc.•Apr 2
Mucopolysaccharidosis Market Analysis Across 7MM — Unveiling Growth Opportunities Across Different Types | DelveInsight
GlobeNewswire Inc.•Feb 18
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight
GlobeNewswire Inc.•Feb 13
Neuroregeneration Therapy Market to Surpass USD 64.8 Billion by 2034, Driven by Advancements in Regenerative Medicine and Rising Neurological Disorders | Transparency Market Research
GlobeNewswire Inc.•Feb 11